Between Aug @ , @ , and Nov @ , @ , @ patients with HCV infection were screened , of whom @ were infected with genotype @ patients were randomly assigned to treatment and received at least one dose of study medication ; @ patients were treatment-naive , of whom @ received ombitasvir plus paritaprevir plus ritonavir and @ received ombitasvir plus paritaprevir plus ritonavir with ribavirin , and @ treatment-experienced patients received the ribavirin-containing regimen .